Neuropsychiatric Symptoms of Epilepsy

18 The Role of Antiepileptic Drugs
357
123. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The
synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Proc Natl Acad Sci U S A. 2004;101(26):9861–6.
124. Muralidharan A, Bhagwagar Z. Potential of levetiracetam in mood disorders: a preliminary
review. CNS Drugs. 2006;20(12):969–79.
125. Zhang W, Connor KM, Davidson JRT. Levetiracetam in social phobia: a placebo controlled
pilot study. J Psychopharmacol Oxf Engl. 2005;19(5):551–3.
126. Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, et al.
Levetiracetam in the management of bipolar depression: a randomized, double-blind,
placebo- controlled trial. J Clin Psychiatry. 2011;72(6):744–50.
127. Stein MB, Ravindran LN, Simon NM, Liebowitz MR, Khan A, Brawman-Mintzer O, et al.
Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled
trial. J Clin Psychiatry. 2010;71(5):627–31.
128. Mattes JA. Levetiracetam in patients with impulsive aggression: a double-blind, placebocontrolled
trial. J Clin Psychiatry. 2008;69(2):310–5.
129. Mula M, Trimble MR, Yuen A, Liu RSN, Sander JWAS. Psychiatric adverse events during
levetiracetam therapy. Neurology. 2003;61(5):704–6.
130. Helmstaedter C, Mihov Y, Toliat MR, Thiele H, Nuernberg P, Schoch S, et al. Genetic variation
in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam.
Epilepsia. 2013;54(1):36–44.
131. Lhatoo SD, Sander JW. The epidemiology of epilepsy and learning disability. Epilepsia.
2001;42 Suppl 1:6–9; discussion 19–20.
132. Besag FMC. Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin
Drug Saf. 2004;3(1):1–8.
133. Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M. Voltage-gated sodium channels
as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol.
2010;9(4):413–24.
134. Delbello MP, Findling RL, Kushner S, Wang D, Olson WH, Capece JA, et al. A pilot controlled
trial of topiramate for mania in children and adolescents with bipolar disorder. J Am
Acad Child Adolesc Psychiatry. 2005;44(6):539–47.
135. Roy Chengappa KN, Schwarzman LK, Hulihan JF, Xiang J, Rosenthal NR, Clinical Affairs
Product Support Study-168 Investigators. Adjunctive topiramate therapy in patients receiving
a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J Clin
Psychiatry. 2006;67(11):1698–706.
136. Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebo-controlled trial of
augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin
Psychopharmacol. 2007;27(6):677–81.
137. Tucker P, Trautman RP, Wyatt DB, Thompson J, Wu S-C, Capece JA, et al. Efficacy and
safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized,
double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(2):201–6.
138. Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, McCague K, et al. A doubleblind,
randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder
in children and adolescents. Am J Psychiatry. 2006;163(7):1179–86.
139. Vasudev A, Macritchie K, Watson S, Geddes JR, Young AH. Oxcarbazepine in the maintenance
treatment of bipolar disorder. Cochrane Database Syst Rev. 2008;(1):CD005171.
140. Vasudev A, Macritchie K, Vasudev K, Watson S, Geddes J, Young AH. Oxcarbazepine for
acute affective episodes in bipolar disorder. Cochrane Database Syst Rev. 2011;(12):CD004857.
141. Bourgeois BFD. Valproate. In: Shorvon S, Perucca E, Engel Jr J, editors. The treatment of
epilepsy. 3rd ed. Chichester: Wiley-Blackwell; 2009. p. 685–98.
142. Kelly KM, Gross RA, Macdonald RL. Valproic acid selectively reduces the low-threshold (T)
calcium current in rat nodose neurons. Neurosci Lett. 1990;116(1–2):233–8.
143. Machado-Vieira R, Ibrahim L, Zarate CA. Histone deacetylases and mood disorders: epigenetic
programming in gene-environment interactions. CNS Neurosci Ther. 2011;17(6):
699–704.